Details of the Drug

General Information of Drug (ID: DMV1BTP)

Drug Name
ISIS-SOD1
Indication
Disease Entry ICD 11 Status REF
Amyotrophic lateral sclerosis 8B60.0 Phase 1 [1]
Motor neurone disease 8B60 Phase 1 [2]
Drug Type
Antisense drug
Cross-matching ID
TTD ID
D05BYO

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
SOD1 messenger RNA (SOD1 mRNA) TTP9K3Q SODC_HUMAN Not Available [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Amyotrophic lateral sclerosis
ICD Disease Classification 8B60.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
SOD1 messenger RNA (SOD1 mRNA) DTT SOD1 2.51E-01 -0.49 -0.43
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
2 ClinicalTrials.gov (NCT01041222) Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations. U.S. National Institutes of Health.